Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 7,169 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 7,169 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $14.50, for a total transaction of $103,950.50. Following the completion of the transaction, the chief executive officer now owns 315,074 shares in the company, valued at approximately $4,568,573. This trade represents a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

KalVista Pharmaceuticals Stock Down 0.7%

Shares of KALV stock traded down $0.10 on Friday, reaching $13.00. 139,291 shares of the stock were exchanged, compared to its average volume of 518,427. The stock has a market cap of $646.06 million, a P/E ratio of -3.57 and a beta of -0.01. The firm has a 50 day moving average of $12.29 and a two-hundred day moving average of $10.72. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors have recently modified their holdings of KALV. Aquatic Capital Management LLC acquired a new position in KalVista Pharmaceuticals during the fourth quarter valued at approximately $44,000. Earned Wealth Advisors LLC purchased a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at $44,000. GAMMA Investing LLC raised its stake in shares of KalVista Pharmaceuticals by 567.3% in the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after acquiring an additional 3,767 shares during the period. CWM LLC lifted its holdings in shares of KalVista Pharmaceuticals by 12,636.1% during the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock valued at $53,000 after acquiring an additional 4,549 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on KALV. Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Finally, Jones Trading reissued a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, KalVista Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).